Navignostics announces new board of directors 

Share this article:

Zurich, Switzerland

Navignostics is delighted to announce the completion of its new board of directors. 

With the closing of the Navignostics 7.5M seed financing round in November 2022 comes a change in the composition of the board of directors. Roland Diggelmann, former CEO of Roche Diagnostics was officially elected as an independent member of the Navignostics board. Dr. Andreas Jenne, a serial entrepreneur with extensive experience in executive roles in different start-up companies and representative of Ventura Biomed Investors was appointed as new chair of the board. The investors are further represented by Dr. Rohan Thakur, president of Bruker Daltonics and expert in global commercial operations in the life science analytical instrument industry. The founders are represented by Prof. Dr. Bernd Bodenmiller, dual professor at the University of Zürich and ETH Zürich and Dr. Stéphane Chevrier, current CSO at Navignostics. 
In addition, Prof. Dr. med. Frank Heppner, neuropathologist at the Charité in Berlin and representative for Think.Health, as well as Andrea Jacobs, current COO of Navignostics, will join the board as observers. 

 For Jana Fischer, CEO of Navignostics, the current composition of the board is ideal to contribute to the successful development of Navignostics in the coming years: “We are extremely happy to have such a strong combination of board members with highly valuable experiences to help us steer towards our shared vision for Navignostics.” 



Navignostics is a spin-off company from the University of Zurich, founded in April 2022, which is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. As a start–up active in the personalized medicine field, Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and to contribute to companion diagnostic development. 


Jana Fischer, Founding CEO :

Explore our services

Each tumor is unique, which is why each cancer patient needs a unique treatment plan. Navignostics helps clinicians identify the optimal therapy from a single tumor tissue section.

The success of clinical trials depends on selecting the right patient group, and Navignostics helps researchers recognize the patients that can benefit the most from their treatment approach.